Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella

Figure 2

The S2-Ag85A oral vaccine can effectively inhibit the replication of Brucella in vitro. (a) The initial inoculation levels of S2, Ag85A, and S2-Ag85A were the same. After 12 hours of infection, the bacterial count was gradually increased in the S2 group from the baseline, and the bacterial count was gradually decreased in the S2-Ag85A. At 24 h and 48 h, the counted level of the virus was significantly decreased in the S2-Ag85A group than in the S2 group ( value < 0.05). (b) The releasing level of LDH in cells of each group at 4 h, 24 h, and 48 h was not significantly differentiated. There was a significantly lower level of LDH in the Ag85A group and S2-Ag85A group than that in the S2 group ( value < 0.05). value < 0.05 compared to the Ag85A group.

(a)

(b)